HLA B7 Antikörper

Produktnummer ABIN1027673

Der Maus Monoklonal Anti-HLA B7-Antikörper wurde für FACS validiert. Er ist geeignet, HLA B7 in Proben von Human und Non-Human Primate zu detektieren. Es sind 5+ Publikationen verfügbar.

Kurzübersicht für HLA B7 Antikörper (ABIN1027673)

Target: HLA B7 (HLA Class I B7 Alpha (HLA B7))

Reaktivität: Human, Non-Human Primate

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser HLA B7 Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS)

Klon: BB7-1

Produktdetails anti-HLA B7 Antikörper

Verwendungszweck: Anti-HLA-B7 Purified

Spezifität: The mouse monoclonal antibody BB7.1 recognizes an extracellular antigen of HLA-B7 antigen. Although highly specific, it can cross-react with HLA-B42 antigen.

Kreuzreaktivität (Details): Human, Non-Human Primates

Aufreinigung: Purified by protein-A affinity chromatography.

Reinheit: > 95 % (by SDS-PAGE)

Immunogen: Papain solubilised HLA-A2, B7

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Flow cytometry: Recommended dilution: 1-4 μg/mL.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2-8°C. Do not freeze.

Referenzen für anti-HLA B7 Antikörper (ABIN1027673)

Cortez-Gonzalez, Sidney, Adotevi, Sette, Millard, Lemonnier, Langlade-Demoyen, Zanetti: "Immunogenic HLA-B7-restricted peptides of hTRT." in: International immunology, Vol. 18, Issue 12, pp. 1707-18, (2006) (PubMed).

de la Salle, Saulquin, Mansour, Klayme, Fricker, Zimmer, Cazenave, Hanau, Bonneville, Houssaint, Lefranc, Naman: "Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP)." in: Clinical and experimental immunology, Vol. 128, Issue 3, pp. 525-31, (2002) (PubMed).

Rini, Selk, Vogelzang: "Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 5, Issue 10, pp. 2766-72, (1999) (PubMed).

Trapani, Vaughan, Tait, McKenzie: "Immunoradiometric assay for the rapid detection of HLA-B27." in: Immunology and cell biology, Vol. 66 ( Pt 3), pp. 215-9, (1991) (PubMed).

Storkus, Alexander, Payne, Dawson, Cresswell: "Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 86, Issue 7, pp. 2361-4, (1989) (PubMed).

Details zu HLA B7

Target: HLA B7 (HLA Class I B7 Alpha (HLA B7))

Andere Bezeichnung: HLA-B7

Hintergrund: HLA-B7 allele of human HLA class I major histocompatibility (MHC) antigen indicates higher risk of breast cancer and cervical cancer. Expression of HLA-B7 together with HLA-B27 is associated with increased susceptibility to spondyloarthropaties. Flow cytometry detection of these two alleles is being used to screen for patients, who suffer from inflammatory disorders affecting the sacroiliac and intervertebral joints, such as ankylosing spondylosis (AS). The HLA-B7 antigen (11 alleles) is expressed in 22 % of healthy Caucasian individuals.

Pathways: Human Leukocyte Antigen (HLA) in Adaptive Immune Response